AstraZeneca heads to euros for more acquisition funding
AstraZeneca, the UK drug maker, hit the euro market on Wednesday after printing $7bn across the Atlantic a day earlier. The borrower is building up funds to pay for its $39bn acquisition of US rival Alexion Pharmaceuticals.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: